Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.
D000818:Animals; D001932:Brain Neoplasms / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D000922:Immunotoxins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015847:Interleukin-4; D019948:Receptors, Interleukin-4 / Q000096:biosynthesis*; D014018:Tissue Distribution